Edition:
United States

Biogen Inc (BIIB.O)

BIIB.O on Nasdaq

343.28USD
21 Aug 2018
Change (% chg)

$-0.83 (-0.24%)
Prev Close
$344.11
Open
$345.70
Day's High
$346.39
Day's Low
$343.00
Volume
625,286
Avg. Vol
1,807,101
52-wk High
$388.67
52-wk Low
$249.17

Chart for

About

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis... (more)

Overall

Beta: 0.89
Market Cap(Mil.): $69,542.10
Shares Outstanding(Mil.): 201.44
Dividend: --
Yield (%): --

Financials

  BIIB.O Industry Sector
P/E (TTM): 17.51 28.28 30.39
EPS (TTM): 19.65 -- --
ROI: 22.04 12.94 12.61
ROE: 34.74 14.96 14.80

Biogen's pricey muscle drug Spinraza too costly for Britain

LONDON Biogen's muscle disease treatment Spinraza has been deemed too expensive for use on Britain's state-run health service, even after a price discount offered by the U.S. drugmaker.

Aug 13 2018

Biogen's pricey muscle drug Spinraza too costly for Britain

LONDON, Aug 14 Biogen's muscle disease treatment Spinraza has been deemed too expensive for use on Britain's state-run health service, even after a price discount offered by the U.S. drugmaker.

Aug 13 2018

Eisai shares fall 18 pct after release of Alzheimer drug test details

TOKYO, July 26 Shares of Japanese drugmaker Eisai fell more than 18 percent on Thursday after the company and its partner Biogen Inc presented the details of their experimental drug on Alzheimer's disease. (Reporting by Hideyuki Sano; Editing by Stephen Coates)

Jul 25 2018

Biogen/Eisai Alzheimer's drug cut cognitive decline by 30 pct -study

CHICAGO, July 25 Biogen Inc and partner Eisai Co Ltd said patients with early-stage Alzheimer's disease treated with their experimental drug BAN2401 experienced 30 percent less cognitive decline than patients who got a placebo in a highly anticipated midstage trial.

Jul 25 2018

Biogen easily tops Street estimates on Spinraza sales, raises forecast

Biogen Inc reported far better-than-expected second quarter profit on Tuesday, driven by strong demand of its Spinraza muscle disease treatment, and the U.S. biotech company raised its full-year profit forecast.

Jul 25 2018

REFILE-UPDATE 3-Biogen easily tops Street estimates on Spinraza sales, raises forecast

* Late-stage trials for Alzheimer's drug aducanumab fully enrolled

Jul 25 2018

Biogen quarterly sales rise 9 pct

July 24 Biogen Inc reported a 9 percent rise in quarterly revenue on Tuesday, helped by demand for its spinal muscular atrophy drug Spinraza.

Jul 24 2018

U.S. jobs growth lifts Wall Street, offsetting tariffs

NEW YORK U.S. stocks climbed on Friday, with the S&P 500 and the Nasdaq hitting their highest levels in two weeks, as strong U.S. jobs growth blunted the impact of an escalating U.S.-China trade dispute. | Video

Jul 06 2018

CORRECTED-US STOCKS-U.S. jobs growth lifts Wall Street, offsetting tariffs

NEW YORK, July 6 U.S. stocks climbed on Friday, with the S&P 500 and the Nasdaq hitting their highest levels in two weeks, as strong U.S. jobs growth blunted the impact of an escalating U.S.-China trade dispute.

Jul 06 2018

US STOCKS-Wall Street buoyed by U.S. jobs growth despite tariffs

* Indexes up: Dow 0.6 pct, S&P 0.9 pct, Nasdaq 1.3 pct (Updates to late afternoon, changes byline, adds NEW YORK to dateline)

Jul 06 2018

Competitors

Earnings vs. Estimates